Clinical trial · Interventional
A Study of Laparoscopic Hepatectomy Versus RFA in the Treatment of Recurrent HCC
A RCT Study of Laparoscopic Hepatectomy Versus RFA in the Treatment of Recurrent HCC
NCT03313648CI-TRIAL-00029950unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To observe and compare the short-term and long-term oncological outcome of laparoscopic hepatectomy and radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma .
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma Recurrent | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Laparoscopic Hepatectomy | Procedure | — | UNRESOLVED |
| Radiofrequency Ablation | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Laparoscopic Hepatectomy
- description
- Improvements in laparoscopic technology mean that LH now has superior short-term efficacy and similar long-term efficacy to open surgery , and LH has shown significant advantages in applications involving recurrent HCC.
- interventionNames
- Procedure: Laparoscopic Hepatectomy
- type
- ACTIVE_COMPARATOR
- label
- Radiofrequency Ablation
- description
- With recent technological advances, RFA has become the most widely investigated new first-line therapeutic option for recurrent HCCs . Numerous large studies have demonstrated the advantages of RFA, which include its ease of use, safety, effectiveness, minimal invasiveness, and minimal morbidity and mortality .
- interventionNames
- Procedure: Radiofrequency Ablation
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Any gender,18 to 70 years old; * Preoperative diagnosis of recurrent HCC clear,liver resection was done previously; * No active hepatitis and decompensated cirrhosis; * Patient with previous liver resection, maximum diameter ≤5cm single recurrent nodules or 3 nodules in diameter and no more than 3cm,did not infringe the portal vein,hepatic vein and inferior vena cava invasion,lymph node or extrahepatic turn; * No tumor rupture or bleeding; * Child-Pugh class A or B grade,ICG-R15 \<20%; * No coagulation disorders,platelet count \> 50 × 109 / L and prolonged prothrombin time \< 5 seconds; * After diagnosis of recurrent HCC,not be including related surgery,radiofrequency ablation (RFA),TACE treatment,no certainty anticancer chemotherapy treatment;supreme absolute contraindications abdominal surgery; * Recurrent nodules are not close to intestines,stomach,cholecyst or diaphragm muscle, not close to the first porta hepatis,main vessel and biliary ducts; * Patients generally available,heart and lung function can tolerate surgery, abdominal surgery supreme absolute contraindications; * Voluntarily participate in the study, voluntarily accept any therapy of two,informed consent. Exclusion Criteria: * Opposite of the above inclusion criteria; * Severe upper abdominal adhesions; * Postoperative pathological examination of the bile duct cell or mixed cell carcinoma and pathologically confirmed positive margin; * Foreign,Hong Kong,Macao,Taiwan and other regions,estimated postoperative difficult to track,followed up; * Nodules proved to be not recurrent HCC during intraoperative exploration, such as:liver metastases of colorectal cancer.
References
Publications (0)
Data not yet available
No reference posted for this study.